Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

After Death Of Cipla Former Joint Managing Director Amar Lulla, Will Vision Of Veteran Continue?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After jointly serving at the helm of Cipla for more than three decades, Joint Managing Director Amar Lulla died April 22 after a prolonged and debilitating battle with cancer. To the world, Cipla Chairman Yusuf Hamied was the face of the company - fighting global pharmaceutical companies to bring down prices of anti-HIV and anti-cancer medications - but to those within the organization, Lulla remained the single driving force, handling the complexities of the generic drugs market in India and working steadily to keep Cipla competitive

Table

View full table

Tags:
Latest Headlines

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

See All
UsernamePublicRestriction

Register

SC077732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By